Literature DB >> 11672119

Enantioselective Synthesis of 3-Deoxy-(R)-sphingomyelin from (S)-1-(4'-Methoxyphenyl)glycerol.

Hoe-Sup Byun1, Jason A. Sadlofsky, Robert Bittman.   

Abstract

(R)-3-Deoxysphingomyelin (2) was prepared from (S)-1-(4'-methoxyphenyl)-glycerol (3). The latter was converted into either p-methoxyphenyl (PMP) (S)-oxiranylmethyl ether (5) or (R)-1-(4'-methoxyphenyl)glycerol 2,3-cyclic sulfate (6). Opening of 5 with lithium pentadecyne in the presence of BF(3).Et(2)O gave PMP (S)-2-hydroxy-4-octadecynyl ether (7) in 65% yield. Alternatively, opening of cyclic sulfate 6 with excess lithium pentadecyne in the presence of catalytic cuprous iodide, followed by acidic workup, gave 7 in 90% yield. After introduction of the amide group via azide displacement, reduction, and N-acylation, simultaneous reduction of the triple bond and deprotection of the PMP group by Birch reduction (Li, EtNH(2)) provided 3-deoxy-N-palmitoyl-(R)-ceramide (9). Finally, phosphitylation of 9, oxidation of the cyclic phosphite with bromine, followed by in situ ring opening gave a (2-bromoethyl)phosphate ester, which on quaternization with aqueous trimethylamine afforded 3-deoxy-N-palmitoyl-(R)-sphingomyelin (2) in 49% overall yield from PMP (S)-2-hydroxy-4-octadecynyl ether (7).

Entities:  

Year:  1998        PMID: 11672119     DOI: 10.1021/jo971977y

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  The 3-hydroxy group and 4,5-trans double bond of sphingomyelin are essential for modulation of galactosylceramide transmembrane asymmetry.

Authors:  Barbara Malewicz; Jacob T Valiyaveettil; Kochurani Jacob; Hoe-Sup Byun; Peter Mattjus; Wolfgang J Baumann; Robert Bittman; Rhoderick E Brown
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

2.  Efficient resolution of 3-aryloxy-1,2-propanediols using CLEA-YCJ01 with high enantioselectivity.

Authors:  Bin Wang; Bin Wu; Bingfang He
Journal:  RSC Adv       Date:  2019-05-03       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.